The Latest Breaking News from Leukemia

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

The Italian dad and Japanese mom of a two-year-old with a rare kind of leukemia have launched a crowdfunding campaign to find a special donor matching their child’s genetic makeup.

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Jerry Ensminger sat in the balcony of the U.S. Senate chamber watching a vote that had begun to feel like a pipe dream.

Scientifically-altered T cells, which produce the body’s immune response, may be a key to defeating leukemia, lymphoma, and multiple myeloma, say authors of a new study.

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Here's a roundup of top developments in the biotech space over the last 24 hours:

John Metchie III, the Houston Texans’ 22-year-old wide receiver, has been diagnosed with leukemia and expects to miss the upcoming season, he announced Sunday.

The Texans rookie receiver starred at Alabama from 2019 to ’21.

Houston Texans WR John Metchie was diagnosed with Acute Promyelocytic Leukemia, which can be a treatable form of cancer.